Renoprotective effects of dulaglutide in patients with T2DM and CKD

TY - JOUR

T1 - Renoprotective effects of dulaglutide in patients with T2DM and CKD

AU - Sorensen, Charlotte M

AU - Holst, Jens J

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.

AB - The AWARD-7 trial shows that the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide, which is not cleared by the kidney, seems to be renoprotective, ameliorates albuminuria and slows estimated glomerular filtration rate decline in patients with type 2 diabetes mellitus and chronic kidney disease, without increasing the risk of hypoglycaemia.

U2 - 10.1038/s41581-018-0055-x

DO - 10.1038/s41581-018-0055-x

M3 - Comment/debate

C2 - 30171207

SN - 1759-5061

VL - 14

SP - 659

EP - 660

JO - Nature Reviews. Nephrology

JF - Nature Reviews. Nephrology

IS - 11

ER -